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ABSTRACT: Obstructive sleep apnoea syndrome (OSAS) often coexists in patients with chronic
obstructive pulmonary disease (COPD). The present prospective cohort study tested the effect of
OSAS treatment with continuous positive airway pressure (CPAP) on the survival of hypoxaemic
COPD patients. It was hypothesised that CPAP treatment would be associated with higher
survival in patients with moderate-to-severe OSAS and hypoxaemic COPD receiving long-term
oxygen therapy (LTOT).
Prospective study participants attended two outpatient advanced lung disease LTOT clinics in
Sa˜o Paulo, Brazil, between January 1996 and July 2006. Of 603 hypoxaemic COPD patients
receiving LTOT, 95 were diagnosed with moderate-to-severe OSAS. Of this OSAS group, 61 (64%)
patients accepted and were adherent to CPAP treatment, and 34 did not accept or were not
adherent and were considered not treated.
The 5-yr survival estimate was 71% (95% confidence interval 53–83%) and 26% (12–43%) in the
CPAP-treated and nontreated groups, respectively (p,0.01). After adjusting for several
confounders, patients treated with CPAP showed a significantly lower risk of death (hazard ratio
of death versus nontreated 0.19 (0.08–0.48)).
The present study found that CPAP treatment was associated with higher survival in patients
with moderate-to-severe OSAS and hypoxaemic COPD receiving LTOT.
KEYWORDS: Chronic obstructive pulmonary disease, continuous positive airway pressure, long-
term oxygen therapy, obstructive sleep apnoea syndrome, survival
C
hronic obstructive pulmonary disease
(COPD) is a common condition that
causes progressive loss of pulmonary
function, and is expected to become the third
leading cause of death worldwide by 2020 [1, 2].
Patients with COPD are more likely to present
with systemic comorbid conditions, including
diabetes and cardiovascular disease [3, 4].
Obstructive sleep apnoea syndrome (OSAS) is
characterised by repetitive occlusions of the
upper airway, resulting in sleep fragmentation,
poor sleep quality, excessive daytime somnolence
and cardiovascular dysfunction [5–7]. OSAS is
common in the general population and often
coexists in patients with COPD (overlap OSAS/
COPD) [8]. Previous studies have demonstrated
that the clinical profile of patients with overlap
OSAS/COPD may be particularly severe, with
such patients showing lower daytime arterial
oxygen tensions (Pa,O2), higher arterial carbon
dioxide tensions (Pa,CO2) and higher pulmonary
arterial pressures than patients with OSAS or
COPD alone [8–10]. Patients with overlap OSAS/
COPD also exhibit increased mortality risk
relative to patients with OSAS alone [11, 12].
Treatment with continuous positive airway pres-
sure (CPAP) improves pulmonary function and
gas exchange in patients with overlap OSAS/
COPD [13, 14]. CPAP treatment may also reduce
mortality in patients with OSAS who do not have
clinically evident COPD [15–18]. Not all studies
show a beneficial effect of CPAP on patients with
OSAS [19], however, and the effects of CPAP on
the treatment of central sleep apnoea are con-
troversial [20]. The impact on survival of CPAP
treatment in patients with concomitant hypox-
aemic COPD is unknown.
Since CPAP is not universally covered by public
health insurance programmes in Brazil and some
covered patients decline its use, there was an
opportunity to conduct a prospective cohort
study comparing the impact on survival of
CPAP use versus nonuse. The patients studied
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had overlap OSAS/COPD and were enrolled in a long-term
oxygen therapy (LTOT) programme for hypoxaemic COPD. It
was hypothesised that treatment with CPAP would be
associated with improved survival in these patients.
MATERIALS AND METHODS
Setting and study subjects
A prospective cohort study was conducted on 95 outpatients
with moderate-to-severe OSAS associated with hypoxaemic
COPD. The patients attended two outpatient advanced lung
diseases LTOT clinics, one at the State Public Hospital of Sa˜o
Paulo and one at Sa˜o Paulo Hospital at the Federal University
of Sa˜o Paulo (both Sa˜o Paulo, Brazil), between January 1996
and July 2006. COPD and hypoxaemia were diagnosed
according to criteria published by the American Thoracic
Society [21] (and subsequently adopted by the Global Initiative
for Chronic Obstructive Lung Disease [22]). Moderate-to-
severe OSAS was diagnosed by clinical symptoms plus a
polysomnographically confirmed apnoea/hypopnoea index
(AHI) of .15 events?h-1 [23].
All patients were managed according to the prevailing
international recommendations for these diseases [22, 24],
receiving education regarding COPD and OSAS care and
pharmacological and nonpharmacological (e.g. supplemental
oxygen) treatment of COPD. According to current guidelines,
smokers are not eligible for LTOT and hence were excluded
from the present analysis, as were patients with cancer
diagnoses or with ,6 months of LTOT use (see Statistical
analysis section).
Baseline data were collected at the time of referral to the LTOT
programme, and included demographics, lung function,
arterial blood gas levels (in room air), body mass index
(BMI), smoking information, hospitalisations due to respira-
tory causes in the previous 12 months and the Charlson
Comorbidity Index [25]. In addition, all patients were classified
as being of low or high socioeconomic risk according to the
Paulista Index of Social Vulnerability, which is a measure of
socioeconomic vulnerability based on the patient’s home
address in Sa˜o Paulo. This socioeconomic vulnerability index
is based on census data collected in 2000 [26]. All lung function
measurements were assessed using post-bronchodilator spiro-
metry according to standard guidelines [27]. Fisher’s exact test
was used to analyse differences between causes of death as a
three-level categorical variable (respiratory, cardiovascular
and other). The study was reviewed and approved by the
local ethics committees of both hospitals.
Confirmation of OSAS and initial CPAP titration
All patients with hypoxaemic COPD and clinical symptoms
and a history strongly suggestive of moderate-to-severe OSAS
(loud snoring, frequent nocturnal arousals, fatigue or excessive
daytime sleepiness, systemic arterial hypertension and obesity)
were routinely referred for split-night polysomnography
(Sonolab 620; Medtron, Sa˜o Paulo, Brazil) [28, 29]. All sleep
studies were performed at the Federal University of Sa˜o Paulo
sleep laboratory, and included continuous monitoring of
electroencephalography, electro-oculography, electromyo-
graphy, nasal canula, abdomen, respiratory effort, oxyhaemo-
globin level measured by pulse oximetry (Sp,O2), snoring and
body position [28, 29].
The AHI was calculated as the total number of respiratory
events (apnoeas plus hypopnoeas) per hour of sleep without
CPAP [23]. Apnoea was defined as complete cessation of
airflow for o10 s, and hypopnoea as a significant reduction in
respiratory symptoms for o10 s associated with arousal or
oxygen desaturation of o3% [23]. Distinction was made
between central hypoventilation related to rapid eye move-
ment sleep and hypopnoea; central hypoventilation includes
long periods of uniform flow reduction and sustained arterial
oxygen desaturation lasting up to several minutes, whereas
hypopnoea generally has a duration of 10–30 s. Moderate-to-
severe OSAS was diagnosed as an AHI of .15 events?h-1.
Patients for whom OSAS was confirmed in the first half of the
sleep study underwent CPAP titration during the second half
of the night according to standard sleep laboratory protocols
[24, 29]. Supplemental oxygen, provided by nasal canula or
adapted nasal mask during the second half of the night [24],
was titrated to achieve an Sp,O2 of .90%.
Since all of the patients were already enrolled in an LTOT
programme, the sleep study was used mainly to confirm OSAS
and titrate CPAP. The levels of oxygen flow were kept constant
in the second half of the study, and flow was increased only if
hypoxaemia was persistent while CPAP was applied. Sleep
stages were scored according to the criteria of RECHTSCHAFFEN
and KALES [30], and arousals were scored according to
American Sleep Disorders Association (now the American
Academy of Sleep Medicine) guidelines [31].
CPAP treatment and follow-up
Although we routinely prescribe CPAP for all hypoxaemic
COPD patients with polysomnographically confirmed
moderate-to-severe OSAS, some patients decline its use due
to cost (it is not a covered expense for patients attending the
Sa˜o Paulo Hospital) or other reasons. Others who accept CPAP
treatment are found not to be adherent upon assessment after
the first 3 months. Only those who report using CPAP for
o5 h?night-1 on o5 nights?week-1 are deemed adherent and
permitted to continue on treatment. For the purposes of the
present analysis, CPAP adherents, as described above,
constitute the CPAP-treated group, whereas all others consti-
tute the nontreated group.
All patients were evaluated quarterly until July 2006 or death.
Cause of death was determined from death certificate
information, if available, or otherwise classified as unknown.
Statistical analysis
Differences between patients in the CPAP-treated and non-
treated groups were compared by unpaired t-test, Wilcoxon
rank-sum test or the Pearson Chi-squared statistic, as appro-
priate. Kaplan–Meier survival curves with log-rank test and
Cox’s proportional hazards model were used to compare
differences in survival. Since determination of CPAP adher-
ence (and hence treatment status) was performed 3 months
after CPAP initiation, which was, on average, 6 months after
initiation of LTOT, the analysis was conditioned on survival
through the first 6 months of LTOT in order to avoid an
immortal time bias [32]. Analyses were adjusted for baseline
characteristics (age, sex, post-bronchodilator forced expiratory
volume in 1 s (FEV1) as a percentage of the predicted value,
Pa,O2, Pa,CO2, obesity (BMI of o30 kg?m-2) and smoking history
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in pack-years), hospitalisations in the past 12 months (0, 1 or
o2), Charlson Comorbidity Index (1, 2 or o3), AHI of
.30 events?h-1, Sp,O2 nadir and the percentage of sleep time
with an Sp,O2 of ,90%. Significance refers to a p-value of
f0.05.
RESULTS
Of 603 patients with hypoxaemic COPD who had received
LTOT for o6 months, 95 (15.7%) fulfilled criteria for
moderate-to-severe OSAS and hence were candidates for
CPAP. Of these 95 patients, 61 were treated with and adherent
to CPAP after 3 months and make up the CPAP-treated group.
The remaining 34 patients were not treated with CPAP (18
patients were offered but declined CPAP, nine patients were
not eligible for CPAP due to lack of insurance coverage and
seven patients had CPAP therapy withdrawn within 3 months
of initiation due to nonadherence).
The study cohort was hypoxaemic and hypercapnic at rest,
showed severe airflow obstruction and had moderate-to-severe
OSAS (table 1). The sleep data presented in table 1 were
acquired during the initial portion of the polysomnographic
study, prior to the start of CPAP titration. CPAP (mean¡SD)
was titrated to 9.8¡1.5 cmH2O. Compared to the CPAP-
treated group, patients not treated with CPAP were older,
exhibited a lower percentage predicted post-bronchodilator
FEV1 and were more likely to have been hospitalised for
respiratory conditions during the previous 12 months. The
proportion of patients classified as high risk based on the
socioeconomic vulnerability index did not differ significantly
between patients in the CPAP-treated and nontreated groups
(13.1 versus 18.2%, respectively; p50.55).
During the follow-up period of regular outpatient care, the
majority of patients did not present with clinical symptoms of
cor pulmonale except during severe COPD exacerbations. Both
groups exhibited significant decreases in the mean¡SD annual
rate of hospitalisations following enrolment in the LTOT
programme compared to the 12-month interval prior to
enrolment (2.1¡1.3 versus 0.3¡0.5; p,0.001 in the CPAP-
treated group; 1.3¡1.0 versus 0.2¡0.4; p,0.001 in the CPAP-
nontreated group). These declines did not differ significantly
between the two groups. Likewise, annual haematocrit levels
in both groups exhibited similar declines toward normal
values (55.1¡5.2 versus 45.1¡2.6%; p,0.001 in the CPAP-
treated group; 54.6¡4.9 versus 45.4¡3.3%; p,0.001 in the
CPAP-nontreated group).
During a median follow-up of 41 months (range 6–106 months),
39 deaths (41% mortality) were observed. This figure was
significantly higher in the CPAP-nontreated group than in the
CPAP-treated group (27 deaths (79.4% mortality) versus 12
deaths (19.7% mortality); p,0.001). Respiratory failure was the
most common (46%) cause of death, followed by cardiovascular
disease (31%) and other causes (10%); in five patients (13% of all
deaths), death certificates were not available and the cause of
death could not be determined. Causes of death for the CPAP-
treated versus nontreated groups were respiratory failure (50
versus 48%), cardiovascular disease (40 versus 30%), other (10
versus 14%) and unknown (20 versus 14%), and did not differ
significantly (p50.36).
TABLE 1 Baseline characteristics of total population and according to obstructive sleep apnoea syndrome treatment group
Total CPAP-treated CPAP-nontreated p-value#
Subjects 95 (100) 61 (64) 34 (36)
Age yrs 64¡8 62¡8 66¡8 0.02
Females 54 (57) 32 (52) 19 (56) 0.75
BMI kg?m-2 34.0¡7.0 34.9¡7.7 32.3¡5.4 0.10
Smoking history pack-yrs 67.3¡33.8 70.8¡35.5 61.1¡30.2 0.30
Pa,O2 mmHg 53.8¡5.6 53.7¡6.2 54.0¡4.5 0.80
Pa,CO2 mmHg 45.9¡6.2 45.3¡6.4 47.0¡5.7 0.20
FEV1 % pred 41.5¡12.2 43.4¡12.3 37.9¡11.3 0.04
Charlson Comorbidity Index
1 22 (23) 17 (28) 5 (15)
2 39 (41) 23 (38) 16 (47) 0.34
o3 34 (36) 20 (34) 13 (38)
Hospitalisations in past year
0 16 (17) 14 (23) 2 (6)
1 44 (46) 30 (49) 14 (41) 0.02
o2 35 (37) 17 (28) 18 (53)
Total AHI events?h-1 43.2¡12.5 43.2¡12.4 43.3¡13.1 0.98
AHI of >30 events?h-1 76 (80) 48 (79) 28 (82) 0.67
Sp,O2 nadir % 64.2¡10.8 64.6¡11.3 63.5¡10.0 0.64
Sleep time" with Sp,O2 of <90% 87.0 85.5 89.6 0.15
Data are presented as n (%) or mean¡SD unless otherwise indicated. CPAP: continuous positive airway pressure; BMI: body mass index; Pa,O2: arterial oxygen tension;
Pa,CO2: arterial carbon dioxide tension; FEV1: forced expiratory volume in 1 s; % pred: % predicted; AHI: apnoea/hypopnoea index; Sp,O2: oxyhaemoglobin level
measured by pulse oximetry. #: two-sided value based on t-test, Pearson Chi-squared test or Wilcoxon rank-sum test as appropriate; ": percentage of total sleep time.
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Kaplan–Meier analysis indicated significantly higher survival
in CPAP-treated patients compared to the nontreated group
(p,0.0001) (fig. 1), with 5-yr survival estimates of 71% (95%
confidence interval (CI) 53–83%) and 26% (12–43%), respect-
ively. On multivariate analysis, higher percentage predicted
post-bronchodilator FEV1, lower Charlson Comorbidity Index
and treatment with CPAP were all significantly associated
with an improved survival experience (table 2). In this
analysis, the hazard ratio for death in CPAP-treated versus
nontreated patients was 0.19 (95% CI 0.08–0.48).
DISCUSSION
To the best of our knowledge, this is the first study to evaluate
the effects of CPAP treatment on survival among patients with
moderate-to-severe OSAS and hypoxaemic COPD who are
receiving LTOT. During a median follow-up of 41 months,
CPAP treatment was associated with significantly higher
survival, even after adjusting for possible confounders at
baseline.
COPD is an increasing cause of death worldwide. The present
study adds to current knowledge by suggesting that the
treatment of moderate-to-severe OSAS in patients with
concomitant hypoxaemic COPD requiring LTOT is associated
with significantly higher survival. Although the present study
was not designed to determine the prevalence of OSAS in this
population, the identification of OSAS in 15.7% of patients
with severe COPD who met criteria for LTOT suggest that this
treatable comorbid condition is present in a significant
proportion of hypoxaemic patients with COPD.
The mortality among severe COPD patients receiving LTOT
was high in the present study, and similar to what has been
previously published [33, 34]. We found no studies that
compared the effects of OSAS treatment in this group of
patients. However, the effects of CPAP on survival in the
present study are comparable to the effects of LTOT in the two
studies that established the importance of oxygen supplemen-
tation in patients with COPD and resting hypoxaemia
(Nocturnal Oxygen Therapy Trial (NOTT) and UK Medical
Research Council (MRC) studies) [33, 34]. In the present study,
the 5-yr survival estimates in the CPAP-treated and nontreated
groups were 71 and 26%, respectively, and, in the combined
MRC and NOTT studies, the 5-yr survival estimates in the
LTOT-treated and nontreated groups were 62 and 16%,
respectively. The main causes of death in the present study
(respiratory failure and cardiovascular disease) are consistent
with those previously reported in patients with severe
hypoxaemic COPD [35].
The benefits of CPAP may arise from improvement in
respiratory mechanics, such as reducing the work of breathing
by minimising hyperinflation. Previous studies have shown
that the use of CPAP improves lung function, gas exchange
and respiratory muscle function, and decreases the risk of
hospitalisations in patients with COPD plus OSAS [13, 14]. It is
also possible that CPAP protects against cardiovascular
disease, particularly since it has been shown that CPAP
reduced cardiovascular mortality in a population of OSAS
patients referred for CPAP treatment [18]. Conversely, COPD
patients were treated with LTOT, and it is possible patients not
treated with CPAP were to some extent protected from the
deleterious effects of the intermittent hypoxia–reoxygenation
injury typical of OSAS.
The extrapolation of data from the general OSAS population to
this particular population with overlap OSAS/hypoxaemic
COPD must be made with caution, however. Intermittent
hypoxia is thought to play a central role in the genesis of
cardiovascular diseases by activating several pathways, such
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FIGURE 1. Kaplan–Meier survival curves comparing continuous positive
airway pressure treated (–––––) versus nontreated patients (?????). The figures
above the x-axis indicate the number of users (nonusers) at risk. The two curves
differed significantly (p,0.0001) based on the log-rank test statistic. LTOT: long-
term oxygen therapy.
TABLE 2 Multivariable Cox’s proportional hazards
regression model
HR (95% CI) p-value
CPAP use# 0.19 (0.08–0.48) ,0.001
Female sex# 2.24 (0.85–5.90) 0.10
Age yrs 1.04 (0.98–1.10) 0.17
Smoking history pack-yrs 1.00 (0.99–1.01) 0.61
Pa,O2 mmHg 0.96 (0.88–1.04) 0.30
Pa,CO2 mmHg 0.94 (0.88–1.01) 0.08
Post-BD FEV1 % pred 0.93 (0.89–0.98) 0.006
Obese# 1.31 (0.64–2.68) 0.45
Hospitalisations in past year n" 0.84 (0.38–1.84) 0.66
Charlson Comorbidity Index+ 1.85 (1.10–3.13) 0.02
AHI of >30 events?h-1# 0.81 (0.28–2.33) 0.69
Sp,O2 nadir % 1.02 (0.98–1.05) 0.34
Sleep time1 with Sp,O2 of <90% 1.00 (0.96–1.03) 0.87
Hazard ratios (HRs) represent the hazard of death for a 1-unit increase in the
predictor variable. CPAP: continuous positive airway pressure; Pa,O2: arterial
oxygen tension; Pa,CO2: arterial carbon dioxide tension; BD: bronchodilator;
FEV1: forced expiratory volume in 1 s; % pred: % predicted; AHI: apnoea/
hypopnoea index; Sp,O2: oxyhaemoglobin level measured by pulse oximetry.
#: reference group was those without this factor/characteristic; ": possible
values were 0 (reference), 1 or o2; +: possible values were 1 (since all patients
have chronic obstructive pulmonary disease; reference group), 2 or o3;
1: percentage of total sleep time.
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as increased sympathetic activity, endothelial dysfunction,
metabolic dysregulation and progression of atherosclerosis
[36]. In the present study, all of the COPD patients were treated
with LTOT and may have been, to some extent, protected from
the deleterious effects of the intermittent hypoxia–reoxygen-
ation injury typical of OSAS.
A strength of the present study is the inclusion of a cohort that
was defined and treated according to well-established criteria
for both COPD and OSAS [21–24]. Additionally, findings
regarding the survival benefit of CPAP treatment persisted
even after adjustment for multiple potential confounders.
Indeed, there was little evidence of confounding; the adjusted
hazard ratio of 0.19 in the present Cox’s model was virtually
identical to the unadjusted hazard ratio of 0.18 (data not
shown). Care was taken to limit the analysis to individuals
with o6 months of follow-up, since this is approximately how
long it took to make a final determination of CPAP treatment
status. This avoided the introduction of an immortal time bias
into the results [32].
The present study has several limitations that may affect the
generalisability of its findings. Most importantly, this is an
observational study; patients were not randomised to receive
or not receive CPAP. In addition, the CPAP-nontreated group
included seven individuals who were withdrawn from CPAP
after 3 months due to nonadherence. As a consequence of
these factors, the CPAP-treated and nontreated groups could
be expected to differ on the basis of a number of factors related
to subsequent survival. Owing to the substantial clinical
evidence that CPAP is an effective treatment of isolated
moderate-to-severe OSAS [15–18], we felt that it would have
been unethical to conduct a randomised trial. Further, the
analysis was adjusted for a number of factors (including
comorbidity, sex, age, smoking history in pack-years, Pa,O2,
Pa,CO2, FEV1, obesity, severity of obstructive sleep apnoea,
number of hospitalisations in the past year and hypoxaemia
during sleep) that may be associated with survival. However,
the possibility cannot be excluded that other unmeasurable
differences between the CPAP-treated and nontreated patients
(e.g. lifestyle factors) may have contributed to the observed
survival advantage in the CPAP-treated group (healthy user
effect) [37].
A second limitation is that, since only patients who required
LTOT were studied, the findings may not be generalisable to
patients with less-severe disease. Thirdly, we had to rely on
self-reported adherence to the CPAP protocol, since most of
the CPAP devices used do not record data on duration of use.
If anything, this probably resulted in overestimation of CPAP
adherence, which, in turn, would have produced a conserva-
tive bias (i.e. towards the null hypothesis). Fourthly, all
patients referred for sleep evaluation underwent a split-night
study rather than separate sleep studies for diagnosis and
titration. To the extent that this practice, which was driven by
cost considerations, resulted in suboptimal CPAP titration,
however, it would also have produced a conservative bias.
Finally, there were no data regarding adherence to LTOT.
However, both groups exhibited clinical improvements in
multiple surrogate end-points that would be expected with
LTOT treatment (significant decrease in the number of
hospitalisations, stabilisation of clinical cor pulmonale and
haematocrit normalisation), suggesting that both groups
benefited from LTOT during the follow-up period.
The present observational study indicates a positive effect of
CPAP treatment on survival in moderate-to-severe OSAS
patients with hypoxaemic COPD receiving LTOT. Given the
survival benefit with CPAP therapy and the prevalence of
moderate-to-severe OSAS (15.7%) found in patients with
hypoxaemic COPD, our study suggests that an active search
for OSAS in patients with hypoxaemic COPD using a screening
questionnaire and/or nocturnal oximetry should be per-
formed. In addition, from a public health perspective, our
study suggests the need for policy makers to include coverage
for CPAP treatment in patients with hypoxaemic COPD,
similar to programmes in place for LTOT in patients with
hypoxaemic COPD.
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